Disinfectant & Biocide

FDA Hand Sanitizer Guidance Withdrawal: Current Requirements

Updated on

U.S. FDA HAND SANITIZER COMPLIANCE UPDATE

FDA withdrew its COVID-19 temporary hand sanitizer guidances effective December 31, 2021. The associated manufacturing and distribution transition periods have ended. Companies supplying the U.S. market must now assess their products against the applicable OTC drug requirements, including manufacturing quality, labelling, registration and listing obligations.

Temporary Policies Withdrawn    OTC Drug Compliance    Registration and Listing

Quick Navigation

Jump to the key sections of this article.

Key Takeaways

  • The withdrawn measures were temporary guidance policies, not product-specific Emergency Use Authorizations.

  • FDA registration, drug listing and an NDC number do not constitute product approval.

  • OMUFA fee liability is assessed separately under the applicable fiscal-year rules.

What FDA Withdrew and Why

FDA announced the withdrawal on October 12, 2021. The three guidances, first issued in March 2020, addressed temporary hand sanitizer preparation, temporary compounding, and manufacture of alcohol for incorporation into alcohol-based hand sanitizers during the COVID-19 public health emergency.

These policies provided temporary regulatory flexibility to help meet demand. FDA cited improved availability of alcohol-based hand sanitizers as the reason the policies were no longer needed. The withdrawal ended that temporary flexibility; continuing commercial manufacture needed to meet the applicable drug requirements.

The Manufacturing and Distribution Deadlines Have Passed

DateEffect of the Withdrawal
December 31, 2021The three guidances were withdrawn. Firms operating under them had to stop the covered production of hand sanitizer and alcohol for use in hand sanitizer.
March 31, 2022Manufacturers had to stop distributing remaining hand sanitizer produced under the temporary policies, including distribution to wholesalers, retailers and hospitals.

FDA's industry Q&A clarified that withdrawal alone did not require retailers to remove all previously supplied stock or trigger a blanket recall. That retail clarification did not extend manufacturers' distribution period. Manufacturers with undistributed temporary-policy products after March 31, 2022, were advised to destroy them and retain disposal records.

Current Requirements for Continued U.S. Supply

Hand sanitizers are regulated as over-the-counter topical antiseptic drugs in the United States. Under the OTC monograph framework, products may be marketed without an approved drug application only when they meet the relevant conditions under section 505G of the Federal Food, Drug, and Cosmetic Act and all other applicable requirements.

Review the intended use, active ingredient, strength, formulation, claims and labelling against the applicable antiseptic conditions. Compliance with a former temporary-policy formulation does not, by itself, establish eligibility for continued marketing. Products outside the applicable monograph framework need assessment of an appropriate drug-application pathway.

Manufacturers must comply with applicable Current Good Manufacturing Practice (CGMP) requirements, including 21 CFR Parts 210 and 211. Quality systems should address raw-material suitability, identity, strength, contamination, finished-product testing and supporting records.

Hand sanitizer safety issues identified by FDA have included unacceptable contaminants such as methanol, benzene and acetaldehyde, microbial contamination and insufficient active-ingredient levels. For current product-specific actions, use FDA's Drug Recalls page to check current product-specific recall information.

Keep Registration, Product Listings and Fee Assessments Current

Companies continuing drug manufacture should maintain accurate establishment registration and product listings using FDA's current drug registration and listing instructions. As FDA explains in its National Drug Code Directory information, registration, listing and assignment of an NDC number do not establish FDA approval or replace the product's substantive compliance assessment.

Discontinuing hand sanitizer does not always mean deregistering the entire establishment. FDA asks firms no longer producing drug products to deregister. A firm continuing to manufacture other drugs should remain registered and update or discontinue the relevant hand sanitizer listings, as appropriate.

Withdrawal of the temporary guidances did not itself trigger OMUFA facility fees. Fee liability and rates are separate matters governed by the applicable annual rules and facility activities. Consult FDA's current OMUFA program information and fiscal-year notices and apply the relevant fiscal-year notice and facility-specific criteria when estimating fees.

How REACH24H Can Help

REACH24H provides U.S. hand sanitizer FDA compliance support for companies reviewing their registration, listing and labelling arrangements. Services include:

  • FDA establishment registration;

  • NDC-related submission support and drug listing;

  • Product label review;

  • Registration and listing updates and renewal support.

Review Your Hand Sanitizer's FDA Compliance Position

Share your product label, active ingredient, intended use and manufacturing arrangements to discuss registration, listing and labelling support for U.S. supply.

Recommended Reading

Official References

REACH24H Disinfectant & Biocide Compliance Team

Written by

REACH24H Disinfectant & Biocide Compliance Team

REACH24H

The disinfectant and biocide team at REACH24H delivers one-stop regulatory compliance services across China, the EU, the US, South Korea and Canada. With 30+ toxicologists and biocidal regulatory experts, we have served 1,000+ companies, providing support for active substance approval, product registration and authorisation, testing coordination, risk assessment and ongoing compliance.

Newsletter Subscription

Sign up to receive event invitations, expert insights, timely news alerts, and other updates.

SUBSCRIBE

Contact Us

REACH24H USA

+1 703 596 8055

REACH24H EU

+353 1 8899 951

REACH24H UK

+44 782 7193124

REACH24H China

+86 571 87103805

REACH24H Korea

+82 2 62451610

REACH24H Japan

+03 5005 0662

REACH24H Singapore

Events

Compliance Strategies for Biocidal Products in Europe, America, China, and South Korea
Full Image

We use cookies to ensure that you have the best browsing experience on our website, analyze the relevance between you and our content, and further understand our privacy policy.